Changes and clinical significance of biochemistry markers in patients with avian influenza A (H7N9) virus infection

doi:10.3969/j.issn.1673-8640.2013.09.004

Abstract

Abstract: Objective To investigate the changes and clinical significance of biochemistry markers in patients with avian influenza A (H7N9) virus infection (2013) before and after treatment. Methods A total of 12 biochemistry markers, including cardiac markers [cardiac troponin T(cTnT), creatine kinase isoenzyme (CK-MB),myoglobin(MYO) and B-type natriuretic peptide(NT-proBNP)],liver function markers [aspartate aminotransferase(AST),alanine aminotransferase(ALT),gamma-glutamyl transpeptidase(GGT),alkaline phosphatase(ALP),total protein(TP) and total bile acid(TBA)] and kidney function markers [creatinine(Cr) and urea nitrogen(BUN)] were determined in 12 cured patients (H7N9 cure group),5 dead patients (H7N9 death group) with avian influenza A (H7N9) virus infection. A total of 50 patients with avian influenza A (H1N1) virus infection (2009) (H1N1 group) and 12 healthy subjects (control group) were enrolled, and the results were analyzed and compared. Results The levels of CK-MB, MYO and NT-proBNP increased in H7N9 cure group and H1N1 group compared with those in control group before the treatment (P<0.05),however,the level of cTnT was normal (P>0.05).The levels of AST, ALT and GGT increased (P<0.05), while those of ALP and TP decreased (P<0.05). The levels of Cr and BUN were normal (P>0.05). Compared with H1N1 group, the increase and decrease degrees for the levels of ALT, ALP, GGT and TP were different, and there was no statistical significance for the other markers (P>0.05). The levels of CK-MB and NT-proBNP in H7N9 death group were higher than those in H7N9 cure group, and the levels of TBA and Cr increased (P<0.05). The levels of CK-MB, MYO, NT-proBNP, AST and TBA decreased after the treatment compared with those before the treatment, and the levels of ALP and TP increased (P<0.05). Compared with the control group, except AST, ALT and GGT, the other markers had no statistical significance in H7N9 cure group after the treatment (P>0.05), and except TP, the other markers had difference in H7N9 death group after the treatment (P<0.05). Conclusions The biochemistry markers may be helpful for the auxiliary diagnosis, progress monitoring and prognosis among the patients with avian influenza A (H7N9) virus infection. The clinical characteristics of biochemistry markers in patients with avian influenza A (H7N9) virus infection are similar with that in patients with avian influenza A (H1N1) virus infection (2009).

Key words: Avian influenza A (H7N9) virus, Infection, Biochemistry marker, Cardiac marker

CLC Number:

R373.1

CHEN Zhijin ,LI Haicong,FANG Huanying,ZHOU Yi,ZHANG Jun.. Changes and clinical significance of biochemistry markers in patients with avian influenza A (H7N9) virus infection[J]. , 2013, 28(9): 749-754.

References

[1] Parry J. H7N9 avian flu infects humans for the first time [J] . BMJ, 2013, 346: f2151.

[2] Parry J. H7N9 avian flu kills seven and infects 23 in China[J] . BMJ, 2013, 346:f2222.

[3] Gao HN,Lu HZ,Cao B,et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection[J] . N Engl J Med,2013,368(24)：2277-2285.

[4] Mandell LA,Wunderink RG,Anzueto A,et al. Infectious Diseases Society of America /American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults [J] . Clin Infect Dis,2007,44(Suppl 2)：S27-S72.

[5] Lu S,Xi X,Zheng Y,et al. Analysis of the clinical characteristics and treatment of two patients with avian influenza virus (H7N9)[J] . Biosci Trends,2013,7(2):109-112.

[6] Tang RB,Chen HL. An overview of the recent outbreaks of the avian-origin influenza A (H7N9) virus in the human [J] . J Chin Med Assoc,2013,76(5): 245-248.

[7] Ke Y,Wang Y,Liu S,et al. High severity and fatality of human infections with avian influenza A (H7N9) infection in China[J] . Clin Infect Dis,2013[Epub ahead of print] .

[8] 鲍琳琳,占玲俊,邓巍,等. 建立H5N1流感病毒感染雪貂动物模型[J] . 中国比较医学杂志,2011,21(9)：40- 44.

[9] 茹永新,杨敬平,李月川,等. 重症甲型H1N1流感病毒肺炎患者多脏器病理研究[J] . 天津医药,2012,40(2)：118-121.

[10] Cao B. What clinicians should know to fight against the novel avian-origin influenza A (H7N9) virus[J] . Chin Med J (Engl),2013,126(12)：2205-2206.

[11] Hu Y,Lu S,Song Z,et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance[J] . Lancet,2013, 381(9885): 2273-2279.

[12] Pacholska-Pytlakowska M. Influenza virus infections[J] . Pol Merkur Lekarski, 2012, 33(197): 265-269.

[13] Puzelli S,Buonaguro FM,Facchini M,et al. Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus[J] . J Clin Microbiol, 2010,48(6): 2298-2300.

[14] 刘欣. 甲型H1N1流感病毒性肺炎病例分析及LDH在流感病毒多脏器损伤机制中的意义 [D] . 河北：河北医科大学,2011.

[15] Carrillo-Esper R,Pérez-Bustos E,Ornelas-Arroyo S,et al. Liver involvement in severe human influenza a H1N1[J] . Ann Hepatol,2010,9(1)：107-111.

[16] 〖JP+4〗Papic N,Pangercic A,Vargovic M,et al. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic[J] . Influenza Other Respi Viruses,2012,6(3)：e2-e5.

[17] 叶应妩,王毓三,申子瑜. 全国临床检验操作规程[M] .第3版.南京：东南大学出版社,2006：337-473.

[18] 陈浩,宓穗卿,赵威. 药物引起肾功能损伤的研究进展[J] . 现代生物医学进展,2012,12(7):1380-1383.